M W Pasmantier
Overview
Explore the profile of M W Pasmantier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keresztes R, Port J, Pasmantier M, Korst R, Altorki N
J Thorac Cardiovasc Surg
. 2003 Dec;
126(5):1603-8.
PMID: 14666040
Objective: Paclitaxel has one of the highest response rates when used as a single agent in patients with esophageal cancer. The combination of paclitaxel and carboplatin has been shown to...
2.
Altorki N, Keresztes R, Port J, Libby D, Korst R, Flieder D, et al.
J Clin Oncol
. 2003 Jul;
21(14):2645-50.
PMID: 12860939
Purpose: Preclinical studies suggest that treatment with a selective cyclo-oxygenase-2 (COX-2) inhibitor may augment the antitumor effects of chemotherapy. In this study, patients with non-small-cell lung cancer (NSCLC) were preoperatively...
3.
Henschke C, Yankelevitz D, McCauley D, Libby D, Pasmantier M, Smith J
Eur Respir J Suppl
. 2003 Feb;
39:45s-51s.
PMID: 12572701
Screening should be considered in lung cancer, more than any other cancer. Not only is the disease highly fatal, essentially incurable, when diagnosed on the prompting of symptoms and/or clinical...
4.
Henschke C, McCauley D, Yankelevitz D, Naidich D, McGuinness G, Miettinen O, et al.
Lancet
. 1999 Jul;
354(9173):99-105.
PMID: 10408484
Background: The Early Lung Cancer Action Project (ELCAP) is designed to evaluate baseline and annual repeat screening by low-radiation-dose computed tomography (low-dose CT) in people at high risk of lung...
5.
McDermott D, Jaffe E, Coleman M, Pasmantier M
Am J Clin Oncol
. 1988 Oct;
11(5):520-3.
PMID: 3177252
The role of debulking surgery as an adjuvant to chemotherapy in advanced ovarian carcinoma was examined. Debulking surgery did not alter the overall response rate to chemotherapy. Surgical resection, though,...
6.
Coleman M, Armitage J, Gaynor M, McDermott D, Weisenburger D, Adler K, et al.
Semin Hematol
. 1988 Apr;
25(2 Suppl 2):23-33.
PMID: 2456620
The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine (COP-BLAM) programs of combination chemotherapy were administered to patients with advanced diffuse large cell lymphoma. The original COP-BLAM programs were designed to deliver...
7.
McDermott D, Galindo A, Sherman R, Jaffe E, Coleman M, Pasmantier M
Cancer Treat Rep
. 1987 Nov;
71(11):1067-9.
PMID: 3677111
Many chemotherapeutic agents are nephrotoxic and/or excreted via the kidney. Thus, careful evaluation of renal function is important since drug dosages are often lowered in patients with impaired renal function....
8.
Coleman M, Gerstein G, TOPILOW A, Lebowicz J, Berhardt B, Chiarieri D, et al.
Semin Hematol
. 1987 Apr;
24(2 Suppl 1):8-20.
PMID: 2438781
Three generations of chemotherapy regimens for the treatment of aggressive lymphomas have evolved in the past decade. The first-generation combination regimen, CVP, also known as COP (cyclophosphamide, vincristine, prednisone), produced...
9.
Pasmantier M, Coleman M, Silver R, Ballard W
Cancer Treat Rep
. 1985 Jun;
69(6):689-93.
PMID: 3926310
Twenty-five patients with previously untreated adenocarcinoma of the ovary (International Federation of Gynecology and Obstetrics, stages II, III, and IV) were placed on a six-drug trial (CHAMP-5) for 18 months....
10.
Coleman M, Pasmantier M, Silver R
Cancer
. 1985 May;
55(10):2342-7.
PMID: 3921228
Twenty-two previously untreated patients with adenocarcinoma of the ovary were treated with 28 day cycles of hexamethylmelamine, Adriamycin (doxorubicin), and cisplatin (HAC) for 9 months followed by three monthly cycles...